A significant difference in patient behavior, based upon the average of investigator ratings on the SKAMP-Deportment scores across all 7 assessments conducted at 1.5, 2.5, 5.0, 7.5, 10.0, 12.0, and 13.0 hours post-dose, were observed between patients when they received VYVANSE compared to patients when they received placebo (Study 3 in Table 6, Figure 4)
Elevated ALT can signal: Non-alcoholic fatty liver disease (NAFLD) Alcohol-related liver damage Hepatitis infections Medication-induced liver injury For people with obesity or diabetes, high ALT often points to fatty liver disease
Q., Sun, H
Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC
Yes, this combination is often used alongside other research peptides, like BPC-157 or TB-500, depending on the studys objectives